Obstructive sleep apnea (OSA) is a disorder defined by intermittent cessations of breathing during sleep. OSA is most often caused by obesity and affects a large population of the United States. Common symptoms include snoring, hypersomnia and nighttime awakening. It has been associated with serious comorbidities such as coronary artery disease, cerebrovascular accidents, and arrhythmias. The proposed mechanisms in which OSA is thought to be pathogenic is through hypoxia, hypercapnia, negative intrathoracic pressure, sympathetic hyperactivity, hypercoagulability, endothelial dysfunction, oxidative stress, microarousal, metabolic and hormonal changes. Often, patients with both OSA and obesity share many of the same biomarkers. CPAP is the gold standard therapy for treating patients with OSA. It is effective at reducing the AHI (Apnea Hypopnea Index) and is indicated for treatment in patients with mild to severe OSA (AHI of 5-30 and >30, respectively). Imaging such as MRI is unnecessary in the diagnosis in OSA however it has been shown to play a role in predicting treatment outcome and for monitoring disease progression.